Literature DB >> 21305617

Genetic modeling of gliomas in mice: new tools to tackle old problems.

Dolores Hambardzumyan1, Luis F Parada, Eric C Holland, Al Charest.   

Abstract

The recently published comprehensive profiles of genomic alterations in glioma have led to a refinement in our understanding of the molecular events that underlie this cancer. Using state-of-the-art genomic tools, several laboratories have created and characterized accurate genetically engineered mouse models of glioma based on specific genetic alterations observed in human tumors. These in vivo brain tumor models faithfully recapitulate the histopathology, etiology, and biology of gliomas and provide an exceptional experimental system to discover novel therapeutic targets and test therapeutic agents. This review focuses on mouse models of glioma with a special emphasis on genetically engineered models developed around key genetic glioma signature mutations in the PDGFR, EGFR, and NF1 genes and pathways. The resulting animal models have provided insight into many fundamental and mechanistic facets of tumor initiation, maintenance and resistance to therapeutic intervention and will continue to do so in the future.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21305617      PMCID: PMC3619979          DOI: 10.1002/glia.21142

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  120 in total

1.  Cancer: stem cells and brain tumours.

Authors:  Peter B Dirks
Journal:  Nature       Date:  2006-12-07       Impact factor: 49.962

Review 2.  Neurofibromin: a general outlook.

Authors:  A B Trovó-Marqui; E H Tajara
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

Review 3.  Platelet-derived growth factor.

Authors:  C H Heldin; A Wasteson; B Westermark
Journal:  Mol Cell Endocrinol       Date:  1985-03       Impact factor: 4.102

Review 4.  Cell transformation by the epidermal growth factor receptor and v-erbB.

Authors:  M J Hayman; P J Enrietto
Journal:  Cancer Cells       Date:  1991-08

5.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Authors:  Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay
Journal:  J Neurosurg       Date:  2006-11       Impact factor: 5.115

6.  Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.

Authors:  Patrick Shannon; Nesrin Sabha; Nelson Lau; Deepak Kamnasaran; David H Gutmann; Abhijit Guha
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

7.  Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

Authors:  D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

8.  The retinoblastoma gene is involved in malignant progression of astrocytomas.

Authors:  J W Henson; B L Schnitker; K M Correa; A von Deimling; F Fassbender; H J Xu; W F Benedict; D W Yandell; D N Louis
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

Review 9.  Using mice to decipher the molecular genetics of brain tumors.

Authors:  Göran Hesselager; Eric C Holland
Journal:  Neurosurgery       Date:  2003-09       Impact factor: 4.654

10.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

View more
  50 in total

1.  PTEN regulation of local and long-range connections in mouse auditory cortex.

Authors:  Qiaojie Xiong; Hysell V Oviedo; Lloyd C Trotman; Anthony M Zador
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

Review 2.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 3.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

4.  Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.

Authors:  J Geraldo Valadez; Anuraag Sarangi; Christopher J Lundberg; Michael K Cooper
Journal:  J Vis Exp       Date:  2014-01-14       Impact factor: 1.355

5.  Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Authors:  John Lynes; Mia Wibowo; Carl Koschmann; Gregory J Baker; Vandana Saxena; A K M G Muhammad; Niyati Bondale; Julia Klein; Hikmat Assi; Andrew P Lieberman; Maria G Castro; Pedro R Lowenstein
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 6.  Brain stem cells as the cell of origin in glioma.

Authors:  Aram S Modrek; N Sumru Bayin; Dimitris G Placantonakis
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 7.  Epidermal growth factor receptor targeting and challenges in glioblastoma.

Authors:  Amy Haseley Thorne; Ciro Zanca; Frank Furnari
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

8.  Evolutionary etiology of high-grade astrocytomas.

Authors:  Yurong Song; Qian Zhang; Burak Kutlu; Simone Difilippantonio; Ryan Bash; Debra Gilbert; Chaoying Yin; T Norene O'Sullivan; Chunyu Yang; Serguei Kozlov; Elizabeth Bullitt; Ken D McCarthy; Tal Kafri; David N Louis; C Ryan Miller; Leroy Hood; Terry Van Dyke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-10       Impact factor: 11.205

Review 9.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

Review 10.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.